Developer of drugable targets and product candidates for the diagnosis and treatment of major chronic inflammatory conditions. The company's core strategy is to study specific endothelial cells, called cuboidals, that line tiny blood vessels in various human inflamed tissues to unlock novel inflammatory pathways and identify target molecules to modulate diseases such as rheumatoid arthritis, Crohn's disease, and allergic inflammatory disorders.
Missing: Endocube's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Endocube's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Endocube Frequently Asked Questions (FAQ)
When was Endocube founded?
Endocube was founded in 2001.
Where is Endocube's headquarters?
Endocube's headquarters is located at Prologue Biotech, Labege.
What is Endocube's latest funding round?
Endocube's latest funding round is Convertible Note - II.
How much did Endocube raise?
Endocube raised a total of $5.7M.
Who are the investors of Endocube?
Investors of Endocube include Biobank Technology Ventures, IRDI Capital Investissement and SOCRI.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.